Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters

Database
Language
Publication year range
1.
Kardiologiia ; 54(3): 46-56, 2014.
Article in Russian | MEDLINE | ID: mdl-25102749

ABSTRACT

Introduction of isoproterenol (an agonist of beta-adrenoreceptors) to rats is one of the widespread experimental models of cardiac failure. It is caused by damage of cardiomyocytes with the subsequent development of substitutive fibrosis. The purpose of the given work was the complex characteristic of cardiac function by means of invasive and noninvasive (echocardiography and impedansometry) methods of research. Isoproterenol was injected twice with a daily interval in dozes 85, 120, 150 or 180 mg/kg. Echocardiographic study of the heart in 2 weeks revealed obvious attributes of cardiac failure (left ventricular dilatation, lowered ejection fraction) in the groups which have received high cumulative dozes of isoproterenol (300-360 mg/kg). The catheterization of the left ventricle in these groups has shown raised enddiastolic pressure, decreased maximal rate of pressure development and fall, and also lowered indices of myocardial contractility and relaxability. In the groups which have received smaller isoproterenol dozes, apparent decrease in relaxability parameters (constants of isovolumic and auxovolumic relaxation) has been revealed at only slightly changed parameters of contractility. A strong correlation between echocardiographic and invasive parameters of myocardial contractility has been found. The phase analysis of the cardiac cycle has shown a lengthening of isometric phases of contraction and relaxation, as well as duration of ejection due to shortening duration of filling of both ventricles. Cardiomyocytes isolated from hearts with obvious cardiac failure responded to electrostimulation by arrhythmic contractions and also by much slowed and incomplete removal of free Ca++ from the myoplasm. Results allow to conclude that relatively smaller extent of myocardial damage is accompanied by decreased relaxability at slightly changed contractility, while at greater degree of damage both processes fail, but delay of relaxation still prevails.


Subject(s)
Heart Failure , Isoproterenol/pharmacology , Myocytes, Cardiac , Adrenergic beta-Agonists/pharmacology , Animals , Cardiac Catheterization/methods , Cardiography, Impedance/methods , Disease Models, Animal , Dose-Response Relationship, Drug , Echocardiography/methods , Heart Failure/chemically induced , Heart Failure/diagnosis , Heart Failure/physiopathology , Male , Models, Cardiovascular , Myocardial Contraction/drug effects , Myocytes, Cardiac/drug effects , Myocytes, Cardiac/pathology , Rats , Rats, Wistar , Statistics as Topic
2.
Kardiologiia ; 51(11): 28-37, 2011.
Article in Russian | MEDLINE | ID: mdl-22117768

ABSTRACT

On the basis of earlier executed studies of hypotensive effect of dinitrosyl iron complexes (DNIC) with glutathione, the drug has been created in industrial conditions named oxacom. Preliminary pharmacological studies of oxacom have not revealed negative qualities. The drug has been now tested in 14 healthy men in whom at single intravenous introduction it caused typical response - a decrease of diastolic as well as systolic arterial pressure on 24-27 mmHg through 3-4 min with subsequent very slow restoration in 8-10 hours. The heart rate after initial rise was quickly normalized. Echocardiography revealed unaltered cardiac output in spite of reduced cardiac filling by 28%. The multilateral analysis of clinical and biochemical data has revealed an absence of essential alterations which could lead to pathological consequences. The drug is recommended for carrying out of the second phase of clinical trial. The comparative study of the efficiency of hypotensive action of oxacom, S-nitrosoglutathione (GS-NO) and sodium nitrite (NO2) in rats has shown that the duration of effect was the greatest at oxacom action.


Subject(s)
Blood Pressure/drug effects , Glutathione , Hypertension/drug therapy , Iron , Nitrogen Oxides , S-Nitrosoglutathione/pharmacokinetics , Sodium Nitrite/pharmacokinetics , Adult , Animals , Biological Availability , Drug Evaluation, Preclinical/methods , Drug Monitoring/methods , Glutathione/administration & dosage , Glutathione/adverse effects , Glutathione/pharmacokinetics , Glutathione/pharmacology , Humans , Hypertension/metabolism , Hypertension/physiopathology , Hypotension/chemically induced , Infusions, Intravenous , Iron/administration & dosage , Iron/adverse effects , Iron/pharmacokinetics , Iron/pharmacology , Male , Nitric Oxide/metabolism , Nitrogen Oxides/administration & dosage , Nitrogen Oxides/adverse effects , Nitrogen Oxides/pharmacokinetics , Nitrogen Oxides/pharmacology , Rats , Rats, Wistar , Therapeutic Equivalency , Therapies, Investigational , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL